NYSE:MYOV - Myovant Sciences Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $31.57
Forecasted Upside: 51.86 %
Number of Analysts: 7
Breakdown:
0 Sell Ratings
4 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$20.79 As of 06/17/2021 04:45 PM ET

▼ -0.28 (-1.33%)

1 month | 3 months | 12 months

Get New Myovant Sciences Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for MYOV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYOV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$31.57

▲ +51.86% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Myovant Sciences in the last 3 months. The average price target is $31.57, with a high forecast of $55.00 and a low forecast of $24.00. The average price target represents a 51.86% upside from the last price of $20.79.

Hold

The current consensus among 7 contributing investment analysts is to hold stock in Myovant Sciences. This rating has held steady since April 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/25/2019

0 strong buy ratings
3 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/24/2020

0 strong buy ratings
3 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/22/2020

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/20/2020

0 strong buy ratings
3 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/19/2020

0 strong buy ratings
3 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/19/2021

0 strong buy ratings
3 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

5/18/2021

0 strong buy ratings
3 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/17/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
5/13/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $24.00	Low	i
5/13/2021	Citigroup	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $24.00	Low	i Rating by Mohit Bansal at Citigroup Inc.
5/3/2021	JPMorgan Chase & Co.	Lower Price Target	Overweight	$38.00 ➝ $32.00	Low	i
2/12/2021	SVB Leerink	Lower Price Target	Market Perform	$28.00 ➝ $26.00	Low	i Rating by A. Fadia at SVB Leerink LLC
1/8/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$30.00 ➝ $28.00	High	i Rating by A. Fadia at SVB Leerink LLC
1/6/2021	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$30.00	N/A	i
12/21/2020	Robert W. Baird	Boost Price Target	Outperform	$24.00 ➝ $30.00	Medium	i
8/12/2020	SVB Leerink	Lower Price Target	Outperform	$29.00 ➝ $28.00	Low	i
7/7/2020	SVB Leerink	Boost Price Target	Outperform	$27.00 ➝ $29.00	High	i
6/23/2020	Evercore ISI	Boost Price Target	Outperform ➝ Positive	$45.00 ➝ $55.00	High	i
6/2/2020	Citigroup	Boost Price Target	Neutral	$9.00 ➝ $20.00	High	i Rating by Mohit Bansal at Citigroup Inc.
6/1/2020	Evercore ISI	Boost Price Target		$30.00 ➝ $35.00	Medium	i
6/1/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$19.00 ➝ $26.00	High	i
5/19/2020	SVB Leerink	Lower Price Target	Outperform	$28.00 ➝ $27.00	High	i
2/10/2020	Cowen	Reiterated Rating	Buy		High	i Rating by Phil Nadeau at Cowen Inc
2/2/2020	Citigroup	Initiated Coverage	Buy ➝ Neutral	$15.00	Medium	i Rating by Mohit Bansal at Citigroup Inc.
11/19/2019	JMP Securities	Reiterated Rating	Buy	$34.00	Low	i Rating by Jason Butler at JMP Securities
11/19/2019	The Goldman Sachs Group	Reiterated Rating	Positive ➝ Buy	$18.00 ➝ $20.00	Medium	i Rating by Paul Choi at The Goldman Sachs Group, Inc.
11/12/2019	Cowen	Reiterated Rating	Buy		High	i Rating by Phil Nadeau at Cowen Inc
10/25/2019	The Goldman Sachs Group	Set Price Target	Buy	$18.00	N/A	i Rating by Paul Choi at The Goldman Sachs Group, Inc.
9/6/2019	Cowen	Reiterated Rating	Buy		High	i Rating by Phil Nadeau at Cowen Inc
8/28/2019	The Goldman Sachs Group	Initiated Coverage	Buy	$20.00	High	i
8/19/2019	SVB Leerink	Initiated Coverage	Outperform	$26.00	High	i Rating by A. Fadia at SVB Leerink LLC
5/30/2019	Citigroup	Initiated Coverage	Buy	$25.00	High	i
4/11/2019	Evercore ISI	Initiated Coverage	Outperform		High	i
2/13/2019	Barclays	Upgrade	Equal Weight ➝ Overweight	$22.00 ➝ $25.00	High	i
2/11/2019	JMP Securities	Reiterated Rating	Buy	$25.00	Low	i
11/19/2018	Citigroup	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $42.00	Medium	i
11/9/2018	Cowen	Reiterated Rating	Buy		High	i
10/26/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$25.00	Medium	i Rating by Dana Flanders at The Goldman Sachs Group, Inc.
9/13/2018	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$39.00	High	i
4/25/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $44.00	Low	i
4/5/2018	Barclays	Downgrade	Overweight ➝ Equal Weight	$18.00	High	i
11/14/2017	Cowen	Reiterated Rating	Buy		N/A	i
11/10/2017	Robert W. Baird	Reiterated Rating	Buy	$20.00	N/A	i
10/4/2017	JMP Securities	Reiterated Rating	Outperform	$23.00 ➝ $25.00	Low	i
10/4/2017	Robert W. Baird	Reiterated Rating	Buy	$20.00	Low	i
10/3/2017	Cowen	Reiterated Rating	Buy		Low	i
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform		High	i
11/21/2016	Cowen	Initiated Coverage	Outperform		N/A	i
11/21/2016	Citigroup	Initiated Coverage	Buy	$17.00	N/A	i
11/21/2016	JMP Securities	Initiated Coverage	Outperform	$23.00	N/A	i
11/21/2016	Barclays	Initiated Coverage	Overweight	$18.00	N/A	i
11/21/2016	Robert W. Baird	Initiated Coverage	Outperform	$20.00	N/A	i

(Data available from 6/17/2016 forward)

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Today's Range

Now: $20.79

$20.67

$21.54

50 Day Range

MA: $21.02

$17.07

$24.56

52 Week Range

Now: $20.79

$13.42

$30.90

Volume

29,796 shs

Average Volume

877,242 shs

Market Capitalization

$1.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Myovant Sciences?

The following Wall Street research analysts have issued stock ratings on Myovant Sciences in the last twelve months: Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Evercore ISI, JPMorgan Chase & Co., Robert W. Baird, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for MYOV.

What is the current price target for Myovant Sciences?

7 Wall Street analysts have set twelve-month price targets for Myovant Sciences in the last year. Their average twelve-month price target is $31.57, suggesting a possible upside of 49.8%. Evercore ISI has the highest price target set, predicting MYOV will reach $55.00 in the next twelve months. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the lowest price target set, forecasting a price of $24.00 for Myovant Sciences in the next year.
View the latest price targets for MYOV.

What is the current consensus analyst rating for Myovant Sciences?

Myovant Sciences currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYOV, but not buy more shares or sell existing shares.
View the latest ratings for MYOV.

What other companies compete with Myovant Sciences?

Other companies that are similar to Myovant Sciences include Evotec, Ascendis Pharma A/S, Ultragenyx Pharmaceutical, Sarepta Therapeutics, Perrigo, Biohaven Pharmaceutical, Schrödinger, Ionis Pharmaceuticals, TG Therapeutics, Legend Biotech, I-Mab, Reata Pharmaceuticals, Galapagos, Blueprint Medicines and Apellis Pharmaceuticals.

How do I contact Myovant Sciences' investor relations team?

Myovant Sciences' physical mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company's listed phone number is 44-20-7400-3351 and its investor relations email address is [email protected] The official website for Myovant Sciences is www.myovant.com.